Can Celcuity Still Lose Less Than Expected When Expectations Are Already Rock Bottom?
Celcuity Inc. (NASDAQ: CELC) reports second quarter 2026 earnings after market close on August 13, 2026, with analysts expecting another quarterly loss as the commercial-stage biotechnology company continues investing in its targeted cancer therapy pipeline. The central question for investors: can the company's lead drug candidate gedatolisib continue demonstrating clinical progress while management maintains its strong cash runway through 2027? With the stock trading at $92.08 and analysts maintaining an overwhelmingly bullish stance despite persistent losses, this report will test whether CELC's long-term promise can offset near-term cash burn concerns.
Part 1: Earnings Preview
Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, with its lead candidate gedatolisib targeting HR-positive, HER2-negative advanced breast cancer. The company operates in the high-stakes oncology space where clinical trial results and regulatory milestones drive valuation.
Celcuity will report Q2 2026 results after the close on Thursday, August 13, 2026. Analysts expect an EPS loss of $-1.08 on minimal revenue. The company most recently reported Q1 2026 EPS of $-0.97, beating estimates of $-1.07 by 9.35%. Compared to Q2 2025's loss of $-1.04, the current estimate of $-1.08 represents a 3.85% deterioration year-over-year, reflecting continued investment in clinical development.
Three key themes define this earnings story:
Clinical Trial Momentum for Gedatolisib: The lead drug candidate has shown promising results in clinical trials for HR-positive, HER2-negative advanced breast cancer treatment. Investors will scrutinize any updates on trial enrollment, efficacy data, or regulatory pathway progress, as these milestones are the primary value drivers for a pre-revenue biotech.
Cash Runway and Burn Rate: With a strong cash position of $387.1 million reported in Q1 2026, management has stated the company is funded through 2027. However, the net loss widened to $46.8 million in Q1 from $34.7 million year-over-year. Investors will watch quarterly burn rate closely to assess whether the 2027 runway remains intact or if capital raises may be needed sooner.
Path to Profitability: Analyst estimates show a dramatic inflection point, with consensus expecting the company to swing from a $-3.76 loss per share in 2026 to $0.02 earnings per share in 2027 — a 100.53% improvement. This quarter's commentary on commercialization timelines and revenue generation will be critical to validating that optimistic outlook.
Analyst commentary ahead of the release remains constructive on the long-term opportunity despite near-term losses. The consensus view emphasizes gedatolisib's differentiated mechanism and the substantial market opportunity in breast cancer, though analysts acknowledge execution risk remains high for a company still in clinical development.
Part 2: Historical Earnings Performance
Celcuity has established a consistent pattern of beating earnings estimates over the past four quarters, though all results remain deeply negative as the company invests in clinical development. In Q2 2025, the company reported a loss of $-1.04 versus estimates of $-0.90, missing by 15.56% — the only miss in the recent sequence. However, the company then delivered three consecutive beats: Q3 2025 ($-0.92 vs. $-1.05, +12.38% beat), Q4 2025 ($-0.97 vs. $-1.06, +8.49% beat), and most recently Q1 2026 ($-0.97 vs. $-1.07, +9.35% beat).
The trend shows improving execution on cost management relative to analyst expectations. While absolute losses remain substantial, the company has consistently come in better than feared over the past three quarters, with beats ranging from 8.49% to 12.38%. This pattern suggests management may have better visibility into operating expenses than the Street, or that analysts are building in conservative cushions.
The sequential stability in reported losses — hovering between $-0.92 and $-1.04 over the past four quarters — indicates relatively predictable cash burn, which is reassuring for investors monitoring the runway to profitability. However, the year-over-year comparison shows losses are not improving, with Q1 2026's $-0.97 essentially flat versus Q1 2025's implied loss level, underscoring that the path to breakeven remains distant.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $-0.90 | $-1.04 | -15.56% | Miss |
| Sep 2025 | $-1.05 | $-0.92 | +12.38% | Beat |
| Dec 2025 | $-1.06 | $-0.97 | +8.49% | Beat |
| Mar 2026 | $-1.07 | $-0.97 | +9.35% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Celcuity typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-14 | +$10.25 (+8.23%) | $14.01 (11.26%) | +$2.96 (+2.20%) | $13.19 (9.79%) |
| 2026-03-25 | +$8.21 (+8.05%) | $7.05 (6.91%) | +$4.59 (+4.16%) | $11.12 (10.09%) |
| 2025-11-12 | +$5.98 (+7.56%) | $5.99 (7.57%) | +$0.85 (+1.00%) | $5.67 (6.66%) |
| 2025-08-14 | -$0.48 (-0.92%) | $2.16 (4.11%) | -$0.10 (-0.19%) | $2.99 (5.77%) |
| 2025-05-14 | +$0.04 (+0.37%) | $0.94 (8.69%) | -$0.34 (-3.13%) | $1.62 (14.92%) |
| 2025-03-31 | -$0.13 (-1.27%) | $1.12 (10.96%) | -$0.82 (-8.11%) | $1.58 (15.63%) |
| 2024-11-14 | -$0.53 (-3.62%) | $1.22 (8.33%) | -$1.45 (-10.28%) | $2.56 (18.14%) |
| 2024-08-14 | -$0.49 (-2.91%) | $1.36 (8.08%) | -$0.56 (-3.43%) | $2.16 (13.23%) |
| Avg Abs Move | 4.12% | 8.24% | 4.06% | 11.78% |
Historical price behavior shows highly volatile post-earnings moves with a strong upward bias in recent reports. Over the past eight earnings releases, the stock has averaged an absolute Day 0 move of 4.12% with an average range of 8.24%, and a Day +1 move of 4.06% with an average range of 11.78%.
The most recent earnings cycles show dramatically amplified volatility. The May 2026 report triggered an 8.23% Day 0 surge with an 11.26% range, followed by a 2.20% Day +1 gain. The March 2026 report produced an 8.05% Day 0 jump and a 4.16% Day +1 continuation. The November 2025 report saw a 7.56% Day 0 gain. This contrasts sharply with the more muted reactions in mid-2024 and early 2025, when moves were typically under 4%.
The pattern suggests the market has become increasingly reactive to CELC's clinical and operational updates, with positive surprises driving substantial rallies. Investors should prepare for potential double-digit intraday swings, particularly if the company provides meaningful updates on gedatolisib's development or cash runway.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 9) |
| Expected Move | $3.87 (4.20%) |
| Expected Range | $88.21 to $95.95 |
| Implied Volatility | 79.44% |
The options market is pricing a 4.20% expected move (±$3.87, range $88.21-$95.95) for the August 21 expiration, which is roughly in line with the 4.12% average Day 0 move but well below the 8.24% average Day 0 range seen historically. This suggests options traders may be underpricing potential volatility given the stock's recent pattern of 8%+ moves on earnings, particularly if clinical trial updates or cash burn commentary surprise the market.
Part 3: What Analysts Are Saying
Analysts maintain an overwhelmingly bullish stance on Celcuity despite the company's ongoing losses. The consensus rating stands at 4.77 out of 5.00 (Strong Buy territory), with 11 Strong Buy ratings, 1 Moderate Buy, and 1 Hold. Zero analysts rate the stock Sell or Strong Sell, reflecting broad conviction in the long-term opportunity.
The average price target of $163.54 implies 77.6% upside from the current price of $92.08, with a range from $148.00 (low) to $178.00 (high). This substantial upside projection reflects analyst confidence that gedatolisib's clinical progress and eventual commercialization will drive significant value creation, despite near-term cash burn.
Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.77. This stability suggests the analyst community is maintaining conviction through the current development phase, viewing the clinical and regulatory pathway as on track. The tight clustering of ratings at the bullish end of the spectrum — with 12 of 13 analysts at Buy or Strong Buy — indicates strong consensus that CELC's risk-reward profile favors patient long-term holders willing to tolerate volatility and ongoing losses as the company advances toward potential commercialization.
Part 4: Technical Picture
Celcuity enters earnings with mixed technical signals that reflect recent weakness from higher levels. The Barchart Technical Opinion currently shows a 72% Sell signal, unchanged from last week but deteriorated from a Hold signal (0%) a month ago. This shift indicates growing near-term technical pressure as the stock has pulled back from earlier 2026 highs.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal suggests near-term momentum has turned negative, though not at extreme levels
- Medium-term (100% Sell): Strong sell signal indicates clear weakness in the intermediate timeframe trend
- Long-term (50% Sell): Moderate sell signal reflects some deterioration in the longer-term trend structure
Trend Characteristics: The combination of Average strength and Average direction suggests the stock is in a typical corrective phase rather than an extreme trending environment, indicating neither panic selling nor strong momentum heading into the report.
The moving average structure confirms the recent pullback. CELC trades at $92.08, above its 5-day ($91.40), 10-day ($90.42), and 20-day ($88.48) moving averages, showing some short-term stabilization. However, the stock remains below its 50-day ($93.62), 100-day ($108.65), and 200-day ($104.99) moving averages, indicating the longer-term trend has deteriorated significantly from the elevated levels seen earlier in 2026.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $91.40 | 50-Day MA | $93.62 |
| 10-Day MA | $90.42 | 100-Day MA | $108.65 |
| 20-Day MA | $88.48 | 200-Day MA | $104.99 |
The key technical level to watch is the 50-day moving average at $93.62, which sits just above the current price and represents nearby resistance. A strong earnings reaction could reclaim this level and potentially trigger a move back toward the 100-day average at $108.65. Conversely, failure to hold the 20-day average at $88.48 could expose the stock to further downside. The overall technical setup is cautionary heading into earnings, with the stock in a corrective phase and below key intermediate-term moving averages, though recent short-term stabilization suggests the selling pressure may be moderating. Given the historical pattern of large post-earnings moves and the current technical weakness, risk management is particularly important for this release.
